These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27166836)

  • 1. Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
    Matsuda Y; Yamauchi T; Hosono N; Uzui K; Negoro E; Morinaga K; Nishi R; Yoshida A; Kimura S; Maekawa T; Ueda T
    Cancer Sci; 2016 Jul; 107(7):1029-38. PubMed ID: 27166836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
    Bandyopadhyay S; Li J; Traer E; Tyner JW; Zhou A; Oh ST; Cheng JX
    PLoS One; 2017; 12(7):e0179558. PubMed ID: 28719608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.
    Okabe S; Tauchi T; Tanaka Y; Sakuta J; Ohyashiki K
    Oncotarget; 2016 Aug; 7(33):53116-53126. PubMed ID: 27437766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification by molecular dynamic simulation and in vitro validation of SISB-A1, N-[1-(4-bromophenyl)-3-methyl-1H-pyrazol-5-yl]-2-[(2-oxo-4-phenyl-2H-chromen-7-yl) oxy], as an inhibitor of the Abl
    Al Shahrani M; Gahtani RM; Abohassan M; Alasmari S; Makkawi M
    Med Oncol; 2023 Oct; 40(11):316. PubMed ID: 37789230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alkynylnicotinamide-Based Compounds as ABL1 Inhibitors with Potent Activities against Drug-Resistant CML Harboring ABL1(T315I) Mutant Kinase.
    Larocque EA; Naganna N; Opoku-Temeng C; Lambrecht AM; Sintim HO
    ChemMedChem; 2018 Jun; 13(12):1172-1180. PubMed ID: 29608815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells.
    Okabe S; Gotoh A
    BMC Cancer; 2023 Sep; 23(1):827. PubMed ID: 37670241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
    Sen R; Natarajan K; Bhullar J; Shukla S; Fang HB; Cai L; Chen ZS; Ambudkar SV; Baer MR
    Mol Cancer Ther; 2012 Sep; 11(9):2033-44. PubMed ID: 22778153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reengineering Ponatinib to Minimize Cardiovascular Toxicity.
    Hnatiuk AP; Bruyneel AAN; Tailor D; Pandrala M; Dheeraj A; Li W; Serrano R; Feyen DAM; Vu MM; Amatya P; Gupta S; Nakauchi Y; Morgado I; Wiebking V; Liao R; Porteus MH; Majeti R; Malhotra SV; Mercola M
    Cancer Res; 2022 Aug; 82(15):2777-2791. PubMed ID: 35763671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear.
    Loren CP; Aslan JE; Rigg RA; Nowak MS; Healy LD; Gruber A; Druker BJ; McCarty OJ
    Thromb Res; 2015 Jan; 135(1):155-60. PubMed ID: 25527332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
    Eide CA; Zabriskie MS; Savage Stevens SL; Antelope O; Vellore NA; Than H; Schultz AR; Clair P; Bowler AD; Pomicter AD; Yan D; Senina AV; Qiang W; Kelley TW; Szankasi P; Heinrich MC; Tyner JW; Rea D; Cayuela JM; Kim DW; Tognon CE; O'Hare T; Druker BJ; Deininger MW
    Cancer Cell; 2019 Oct; 36(4):431-443.e5. PubMed ID: 31543464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the mechanism of USP28-mediated IFITM3 elevation in BCR-ABL-dependent imatinib resistance in CML.
    Li Z; Xi Y; Tu L; Zhang X; Huang Y; Nie H; Peng C; Chai H; Zeng S; Zheng X; Cheng L
    Biomed Pharmacother; 2024 Apr; 173():116315. PubMed ID: 38394852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells.
    Orsolic N; Golemovic M; Quintás-Cardama A; Scappini B; Manshouri T; Chandra J; Basic I; Giles F; Kantarjian H; Verstovsek S
    Cancer Sci; 2006 Sep; 97(9):952-60. PubMed ID: 16822295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical characteristics of chronic myeloid leukemia with T315I mutation and the efficacy of ponatinib].
    Chen C; Xu N; Jiang X; Wu W; Zhou X; Liu L; Huang J; Yin C; Cao R; Liao L; Xu D; Zhang Y; Liu Q; Liu X
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Mar; 39(3):364-368. PubMed ID: 31068313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ponatinib-review of historical development, current status, and future research.
    Kantarjian HM; Chifotides HT; Haddad FG; Short NJ; Loghavi S; Jabbour E
    Am J Hematol; 2024 Aug; 99(8):1576-1585. PubMed ID: 38727135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
    Jabbour E; Apperley J; Cortes J; Rea D; Deininger M; Abruzzese E; Chuah C; DeAngelo DJ; Hochhaus A; Lipton JH; Mauro M; Nicolini F; Pinilla-Ibarz J; Rosti G; Rousselot P; Shah NP; Talpaz M; Vorog A; Ren X; Kantarjian H
    Leukemia; 2024 Mar; 38(3):475-481. PubMed ID: 38287132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isoalantolactone mediates the degradation of BCR-ABL protein in imatinib-resistant CML cells by down-regulating survivin.
    Yin SS; Chen C; Liu Z; Liu SL; Guo JH; Zhang C; Zhang QW; Gao FH
    Cell Cycle; 2023 Jun; 22(12):1407-1420. PubMed ID: 37202916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia.
    Kumar R; Pereira RS; Zanetti C; Minciacchi VR; Merten M; Meister M; Niemann J; Dietz MS; Rüssel N; Schnütgen F; Tamai M; Akahane K; Inukai T; Oellerich T; Kvasnicka HM; Pfeifer H; Nicolini FE; Heilemann M; Van Etten RA; Krause DS
    Leukemia; 2020 Aug; 34(8):2087-2101. PubMed ID: 32439895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of K562 cells: uncovering novel chromosomes, assessing transferrin receptor expression, and probing pharmacological therapies.
    Karagiannis TC; Wall M; Ververis K; Pitsillou E; Tortorella SM; Wood PA; Rafehi H; Khurana I; Maxwell SS; Hung A; Vongsvivut J; El-Osta A
    Cell Mol Life Sci; 2023 Aug; 80(9):248. PubMed ID: 37578596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S1P Signaling Genes as Prominent Drivers of BCR-ABL1-Independent Imatinib Resistance and Six Herbal Compounds as Potential Drugs for Chronic Myeloid Leukemia.
    Morang S; Bisht M; Upadhyay V; Thapliyal S; Handu S
    OMICS; 2024 Jul; 28(7):367-376. PubMed ID: 38986084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular vesicle-mediated regulation of imatinib resistance in chronic myeloid leukemia via the miR-629-5p/SENP2/PI3K/AKT/mTOR axis.
    Jiang Y; Xiao S; Huang S; Zhao X; Ding S; Huang Q; Xiao W; Li Z; Zhu H
    Hematology; 2024 Dec; 29(1):2379597. PubMed ID: 39056503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.